Evaluation of Mass Drug Administration to Eliminate Lymphatic Filariasis in Surguja and Surajpur District, Chhattisgarh

Published

2022-06-30

DOI:

https://doi.org/10.47203/IJCH.2022.v34i02.022

Keywords:

Lymphatic Filariasis, Mass Drug Administration Compliance, Coverage

Dimensions Badge

Issue

Section

Original Article

Authors

Abstract

Background: Mass Drug Administration of a single dose of DEC was launched on June 5, 2004 by the Government of India. MDA coverage increased gradually from 72.42% in 2004 to 88.96% in 2014. However, compliance has remained relatively low in most of the endemic areas as in 9 endemic Districts in State of Chhattisgarh. In Chhattisgarh State, Lymphatic Filariasis affected 14,818 people in the year 2011 and 13921 in the year 2013 with demonstrated manifestation. Objectives: To assess the coverage and compliance along with factors affecting compliance regarding MDA implementation in Surguja and Surajpur District of Chhattisgarh. Methods: A cross-sectional descriptive study was conducted from July-September 2021 in two district of Chhattisgarh. The division of segments and selection of the households was done based on the WHO criteria of coverage evaluation survey field guide in which from 30 villages, 450 households were covered. Result:  The overall coverage rate was 95.55% in Surguja and 89.16% in Surajpur District. The overall compliance was 89.3% with Coverage-Compliance gap of 4.12. The Effective Coverage Rate was 89.3% in 2243 eligible population of Surguja and Surajpur District. Coverage and Compliance was found more in females as compared to males but was found to be statistically not significant.  Coverage and Compliance was found more in Surguja district as compared to Surajpur district. Conclusion: Training programme for drug distributors should emphasize more on how to address the fear of side effects among beneficiaries and other reasons of low compliance for the benefit of the MDA programme.

How to Cite

1.
Mendhe HG, Prasad MA, Potdar P, Verma A. Evaluation of Mass Drug Administration to Eliminate Lymphatic Filariasis in Surguja and Surajpur District, Chhattisgarh. Indian J Community Health [Internet]. 2022 Jun. 30 [cited 2022 Aug. 17];34(2):265-9. Available from: https://www.iapsmupuk.org/journal/index.php/IJCH/article/view/2345

Downloads

Download data is not yet available.

References

Fitzpatrick C, Engels D. Leaving no one behind: a neglected tropical disease indicator and tracers for the Sustainable Development Goals. Int Health. 2016; 8 Suppl 1(Suppl 1):i15-8.

Government of India. Operational guidelines on elimination of lymphatic filariasis. Directorate NVBDCP, 22. Shamnath Marg, Delhi 110054, India; 2005.

Cases of Filaria/Lymphatic Filariasis- PIB. Available at https://pib.gov.in/newsite/PrintRelease.aspx?relid=104117

World health organization. Monitoring and epidemiological assessment of the programme to eliminate lymphatic Filariasis at implementation unit level 2005 (http://www.whqlibdoc.who.int/hq/2005/who_cds_ cpe_cee_2005.50.pdf ).

MDA coverage: National Vector Borne Disease Control Programme Director General of Health Services Ministry of Health &Family Welfare. Available from http://www.nvbdcp.gov.in/fil-mda.html .

Ramaiah KD, Das PK, Appavoo NC, Ramu K, Augustin DJ, Kumar KN, Chandrakala AV: A programme to eliminate lymphatic Filariasis in Tamil Nadu state, India; compliance with annual single-dose DEC mass treatment and some related operational aspects. Trop Med Int Health 2000, 5:842-7.

Srivastava PK, Bhattacharjee J, Dhariwala AC, Krishnamoorthy K, Dash AP. Elimination of Lymphatic Filariasis – Current Status and Way Ahead. J Commun. Dis. 2014; 46(2): 85- 94.

Kumar SP. Lymphatic Filariasis in India: A Journey towards Elimination. J Commun Dis 2020; 52(3): 17-21

Babu, Bontha & Babu G, Retheesh. (2014). Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: A systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene. 108. 10.1093/trstmh/tru057.

World health organization. Coverage surveys for preventive chemotherapy: guidelines for implementation. 2016.

Ministry of Health and Family Welfare, Government of India. Filariasis Control in India and Its Elimination (Internet). Available from: http://nvbdcp.gov.in/doc/guidelines-filariasis-elimination-india.pdf

Bhatia V, Giri PP, Sahoo SS, Preeti PS, Sahu DP. Mass Drug Administration (MDA) for Elimination of Lymphatic Filariasis: Experiences from Nayagarh District of Odisha, India. Indian J Comm Health. 2018; 30, 3: 287-292.

Kulkarni P, Kumar R, Rajegowda RM, Channabasappa HG, Ashok NC. MDA Program against lymphatic fi lariasis: Are we on the path to success? Experience from Uttara Kannada District, Karnataka. Int J Med Public Health 2014;4:243-6.

Gururaj NA, Ramesh, Ajaykumar G, Ravikumar K, Devendrappa BG. Coverage Evaluation Survey of Mass Drug Administration Strategy to Eliminate Lymphatic Filariasis in North Karnataka Region. Are We on Track? Ann Community Health 2020;8(4):1-6.

Shivalingaiah AH, Ravikumar K, Gurupadaswamy SM. Evaluation of coverage and compliance to mass drug administration for lymphatic filariasis elimination in two endemic districts of Karnataka. Int J Community Med Public Health 2019;6:3583-7.

Hoolageri MS, Kamath R, Ravikumar K, Jagadish G, Kamath S. Evaluation of mass drug administration programme for elimination of lymphatic filariasis in Bidar district, Karnataka. Int J Community Med Public Health 2018;5:1020-3.

Mane VP, Bhovi RA. Evaluation of mass drug administration against lymphatic filariasis in Bidar district, Karnataka, India. Int J Community Med Public Health 2018;5:4107-11.

Banerjee S, Bandyopadhyay K, Khan MF, et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: A mixed method study. J Family Med Prim Care. 2019;8(9):3009-3014. doi:10.4103/jfmpc.jfmpc_503_19

Hussain MA, Sitha AK, Swain S, Kadam S, Pati S. Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance. Infectious Diseases of Poverty 2014 3:31.